FR14C0080I2 - Methode d'administration d'un anticorps - Google Patents

Methode d'administration d'un anticorps

Info

Publication number: FR14C0080I2
Authority: FR; France
Prior art keywords: antibody administration; antibody; administration
Prior art date: 2000-04-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0080C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Millennium Pharmaceuticals Inc

Original Assignee

Genentech Inc

Millennium Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-14

Filing date

2014-11-13

Publication date

2015-10-30

2014-11-13 Application filed by Genentech Inc, Millennium Pharmaceuticals Inc filed Critical Genentech Inc

2014-12-19 Publication of FR14C0080I1 publication Critical patent/FR14C0080I1/fr

2015-10-30 Application granted granted Critical

2015-10-30 Publication of FR14C0080I2 publication Critical patent/FR14C0080I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Transplantation (AREA)
Obesity (AREA)

FR14C0080C 2000-04-14 2014-11-13 Methode d'administration d'un anticorps Active FR14C0080I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US55008200A	2000-04-14	2000-04-14
US09/748,960 US20010046496A1 (en)	2000-04-14	2000-12-27	Method of administering an antibody
PCT/US2001/012234 WO2001078779A2 (en)	2000-04-14	2001-04-13	Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease

Publications (2)

Publication Number	Publication Date
FR14C0080I1 FR14C0080I1 (da)	2014-12-19
FR14C0080I2 true FR14C0080I2 (fr)	2015-10-30

Family

ID=27069332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0080C Active FR14C0080I2 (fr)	2000-04-14	2014-11-13	Methode d'administration d'un anticorps

Country Status (16)

Country	Link
US (5)	US20010046496A1 (da)
EP (3)	EP2298348B9 (da)
JP (3)	JP2003531129A (da)
AU (1)	AU2001251629A1 (da)
BE (1)	BE2017C009I2 (da)
CA (1)	CA2406220C (da)
CY (3)	CY1113489T1 (da)
DK (2)	DK1278543T3 (da)
ES (2)	ES2609689T3 (da)
FR (1)	FR14C0080I2 (da)
HK (1)	HK1054320A1 (da)
LU (1)	LUC00014I2 (da)
MX (1)	MXPA02010059A (da)
NL (1)	NL300702I2 (da)
PT (1)	PT2298348T (da)
WO (1)	WO2001078779A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
JP2005526045A (ja) *	2002-02-25	2005-09-02	エランファーマシューティカルズ，インコーポレイテッド	炎症の治療用薬剤の投与
SG165158A1 (en)	2002-05-02	2010-10-28	Wyeth Corp	Calicheamicin derivative-carrier conjugates
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
CA2552523C (en) *	2004-01-09	2019-11-26	Pfizer Inc.	Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
DK2990422T3 (da) *	2004-09-03	2018-09-17	Genentech Inc	Humaniserede anti-beta7-antagonister og anvendelser herfor
ES2351057T3 (es)	2005-07-08	2011-01-31	Pfizer Limited	Anticuerpos contra madcam.
WO2007007152A2 (en) *	2005-07-11	2007-01-18	Pfizer Limited	Anti-madcam antibodies to treat metastatic cancers and chloroma
BRPI0613459A2 (pt) *	2005-07-11	2011-01-11	Pfizer Ltd	combinação de anticorpo anti-madcam e inibidor de caspase antifibrótica para tratar fibrose hepática
CN105037549B (zh) *	2007-01-11	2018-09-28	诺和诺德公司	抗-kir抗体、制剂及其应用
WO2008115504A2 (en) *	2007-03-20	2008-09-25	Millennium Pharmaceuticals, Inc.	Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
US20110105724A1 (en) *	2007-08-16	2011-05-05	Stephanie Jane Clegg	Novel compounds
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
DK2279004T3 (da) *	2008-05-16	2015-02-02	Hoffmann La Roche	Anvendelse af biomarkører til vurdering af behandling af gastrointestinale inflammatoriske forstyrrelser med beta7-integrinantagonister
MY184957A (en)	2009-03-20	2021-04-30	Amgen Inc	Alpha-4-beta-7 heterodimer specific antagonist antibody
EP3578205A1 (en)	2010-08-06	2019-12-11	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt)	2010-10-01	2019-09-24	Moderna Therapeutics Inc	ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
PT2704742T (pt) *	2011-05-02	2017-11-15	Millennium Pharm Inc	Formulação de um anticorpo anti-a47
UA116189C2 (uk) *	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CA2850624A1 (en)	2011-10-03	2013-04-11	Moderna Therapeutics, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012340621B2 (en) *	2011-11-23	2017-10-12	Amgen Inc.	Administration of alpha4beta7 hetero-dimer-specific antibody
US20130156849A1 (en)	2011-12-16	2013-06-20	modeRNA Therapeutics	Modified nucleoside, nucleotide, and nucleic acid compositions
EA034583B1 (ru) *	2012-01-12	2020-02-21	Милленниум Фармасьютикалз, Инк.	ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en)	2012-04-02	2015-11-24	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2922554T (pt)	2012-11-26	2022-06-28	Modernatx Inc	Arn modificado nas porções terminais
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3581585A1 (en)	2014-11-26	2019-12-18	Millennium Pharmaceuticals, Inc.	Vedolizumab for the treatment of fistulizing crohn's disease
EP3237004B1 (en)	2014-12-24	2024-05-08	Takeda Pharmaceutical Company Limited	Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
WO2017160699A2 (en)	2016-03-14	2017-09-21	Millennium Pharmaceuticals, Inc.	Method of preventing graft versus host disease
CN117298268A (zh)	2016-03-14	2023-12-29	千禧制药公司	治疗或预防移植物抗宿主疾病的方法
US11760803B2 (en)	2016-03-24	2023-09-19	Takeda Pharmaceutical Company Limited	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh)	2016-03-24	2017-10-16	千禧製藥公司	治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3452070A1 (en)	2016-05-04	2019-03-13	Millennium Pharmaceuticals, Inc.	Triple combination therapy for treating inflammatory bowel disease
WO2017218434A1 (en)	2016-06-12	2017-12-21	Millennium Pharmaceuticals, Inc.	Method of treating inflammatory bowel disease
BR112020000698A2 (pt)	2017-07-14	2020-07-14	Pfizer Inc.	anticorpos contra madcam
US20230139938A1 (en) *	2021-09-21	2023-05-04	University Of South Carolina	Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
JP3101690B2 (ja) *	1987-03-18	2000-10-23	エス・ビィ・２・インコーポレイテッド	変性抗体の、または変性抗体に関する改良
DE3856559T2 (de)	1987-05-21	2004-04-29	Micromet Ag	Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5403919A (en) *	1987-08-11	1995-04-04	Board Of Trustees Of The Leland Stanford Junior University Stanford University	Method to control leukocyte extravasation
US5538724A (en) *	1987-08-11	1996-07-23	The Board Of Trustees For The Leland Stanford Junior Univ.	Method of control leukocyte extravasation
WO1989007142A1 (en)	1988-02-05	1989-08-10	Morrison Sherie L	Domain-modified constant region antibodies
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
EP0940468A1 (en) *	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
DE69407758T3 (de) *	1993-02-09	2007-05-24	Biogen Idec Ma Inc., Cambridge	Antikörper zur behandlung von insulinabhängigem diabetes
CA2115811A1 (en)	1993-02-17	1994-08-18	Claus Krebber	A method for in vivo selection of ligand-binding proteins
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) *	1994-08-12	1998-07-15	Flexpharm Ltd	Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) *	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) *	1996-01-23	2000-01-18	Abbott Laboratories	Reagents for use as calibrators and controls
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
ATE549918T1 (de)	1996-12-03	2012-04-15	Amgen Fremont Inc	Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
EA004270B1 (ru) *	1998-09-14	2004-02-26	Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем	Способы лечения множественной миеломы и индуцированной миеломой резорбции костей с помощью антагонистов интегрина

2000
- 2000-12-27 US US09/748,960 patent/US20010046496A1/en not_active Abandoned
2001
- 2001-04-13 EP EP10010997.4A patent/EP2298348B9/en not_active Expired - Lifetime
- 2001-04-13 EP EP16191558.2A patent/EP3167902B1/en not_active Revoked
- 2001-04-13 EP EP01925028A patent/EP1278543B1/en not_active Expired - Lifetime
- 2001-04-13 DK DK01925028.1T patent/DK1278543T3/da active
- 2001-04-13 CA CA2406220A patent/CA2406220C/en not_active Expired - Lifetime
- 2001-04-13 MX MXPA02010059A patent/MXPA02010059A/es active IP Right Grant
- 2001-04-13 ES ES10010997.4T patent/ES2609689T3/es not_active Expired - Lifetime
- 2001-04-13 AU AU2001251629A patent/AU2001251629A1/en not_active Abandoned
- 2001-04-13 PT PT100109974T patent/PT2298348T/pt unknown
- 2001-04-13 ES ES01925028T patent/ES2398096T3/es not_active Expired - Lifetime
- 2001-04-13 DK DK10010997.4T patent/DK2298348T3/da active
- 2001-04-13 WO PCT/US2001/012234 patent/WO2001078779A2/en active Application Filing
- 2001-04-13 JP JP2001576078A patent/JP2003531129A/ja not_active Withdrawn
2003
- 2003-07-29 HK HK03105456.3A patent/HK1054320A1/xx unknown
- 2003-12-15 US US10/735,863 patent/US20050095238A1/en not_active Abandoned
2011
- 2011-08-05 US US13/204,139 patent/US20120034243A1/en not_active Abandoned
2012
- 2012-05-02 JP JP2012105379A patent/JP5764524B2/ja not_active Expired - Lifetime
- 2012-12-18 CY CY20121101236T patent/CY1113489T1/el unknown
2014
- 2014-02-03 US US14/171,161 patent/US20140186345A1/en not_active Abandoned
- 2014-11-11 NL NL300702C patent/NL300702I2/nl unknown
- 2014-11-13 FR FR14C0080C patent/FR14C0080I2/fr active Active
- 2014-11-17 CY CY2014046C patent/CY2014046I2/el unknown
2015
- 2015-01-19 JP JP2015007655A patent/JP6021959B2/ja not_active Expired - Lifetime
2017
- 2017-01-05 CY CY20171100013T patent/CY1118429T1/el unknown
- 2017-04-11 BE BE2017C009C patent/BE2017C009I2/nl unknown
- 2017-04-11 LU LU00014C patent/LUC00014I2/fr unknown
2018
- 2018-11-02 US US16/179,157 patent/US20200002423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1118429T1 (el)	2017-06-28
AU2001251629A1 (en)	2001-10-30
NL300702I1 (da)	2016-01-28
JP6021959B2 (ja)	2016-11-09
JP2012184241A (ja)	2012-09-27
CA2406220A1 (en)	2001-10-25
PT2298348T (pt)	2017-01-04
US20050095238A1 (en)	2005-05-05
ES2609689T3 (es)	2017-04-21
WO2001078779A3 (en)	2002-07-04
CY1113489T1 (el)	2016-04-13
LUC00014I1 (da)	2017-04-18
US20120034243A1 (en)	2012-02-09
DK2298348T3 (da)	2017-01-30
FR14C0080I1 (da)	2014-12-19
JP2003531129A (ja)	2003-10-21
MXPA02010059A (es)	2004-08-19
US20200002423A1 (en)	2020-01-02
CY2014046I1 (el)	2016-04-13
EP2298348A1 (en)	2011-03-23
EP2298348B9 (en)	2017-02-15
US20010046496A1 (en)	2001-11-29
EP3167902B1 (en)	2020-07-29
CY2014046I2 (el)	2016-04-13
WO2001078779A2 (en)	2001-10-25
EP1278543A2 (en)	2003-01-29
CA2406220C (en)	2019-02-12
DK1278543T3 (da)	2013-01-14
HK1054320A1 (en)	2003-11-28
BE2017C009I2 (da)	2017-09-22
JP5764524B2 (ja)	2015-08-19
NL300702I2 (da)	2016-01-28
ES2398096T3 (es)	2013-03-13
US20140186345A1 (en)	2014-07-03
EP2298348B1 (en)	2016-10-12
EP1278543B1 (en)	2012-09-19
LUC00014I2 (da)	2017-06-19
EP3167902A1 (en)	2017-05-17
JP2015083603A (ja)	2015-04-30

Publication	Publication Date	Title
FR14C0080I2 (fr)	2015-10-30	Methode d'administration d'un anticorps
CY2013011I2 (el)	2015-08-05	Μεθοδος χορηγησης διφωσφονικων
DE60121953D1 (de)	2006-09-14	Herstellungsverfahren von arzneizubereitungen
MA27126A1 (fr)	2005-01-03	3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
ID25792A (id)	2000-11-02	Antibodi-antibodi terhadap cd40 manusia
CY2014003I2 (el)	2015-12-09	Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
NO20071303L (no)	2001-07-27	Farmasoytiske preparater
NO20025450L (no)	2002-11-14	Ny farmasöytisk sammensetning
IS6688A (is)	2003-01-16	Lyfjafræðilegar samsetningar af kólesterýl ester flutningspróteinhindrum
ID30590A (id)	2002-01-03	Celana sekali pakai jenis-celana pendek
EE200200393A (et)	2003-10-15	Glüburiidi ravimkoostis
ID30187A (id)	2001-11-15	Dongkrak jenis pantagraf
DE50104433D1 (de)	2004-12-09	Desodorierende Zubereitungen
MA26882A1 (fr)	2004-12-20	COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
NO20002686D0 (no)	2000-05-25	Forbedring av Peyronies sykdom
DE60126814D1 (de)	2007-04-05	Inhalation von stickoxid
EE200300218A (et)	2003-08-15	Latentse antitrombiin III valmistamise meetod
ITBO20000446A0 (it)	2000-07-21	Unita' e metodo di trasferimento di spezzoni di sigaretta .
NO20010490D0 (no)	2001-01-29	Inhibisjon av ''graft-versus-host''-sykdom
FR2816843B1 (fr)	2006-10-27	Inhibiteurs de l'enzyme 5 alpha-reductase
DE60132362D1 (de)	2008-02-21	Herstellung von ultradünnwandigen cordierit-strukturen
DE60142051D1 (de)	2010-06-17	Herstellung von perfluorolefinen
FR2824092B1 (fr)	2004-04-09	Ensemble d'elements de construction
MA27184A1 (fr)	2005-01-03	Dosage d'anticorps anti-ingap
FR2822846B1 (fr)	2004-01-23	Procede de preparation et de selection d'anticorps